Navigation Links
BUMC, BMC receives Clinical and Translational Science Award from NIH
Date:5/29/2008

Boston, MA--The National Institutes of Health (NIH) has awarded one of 14 Clinical and Translational Science Awards (CTSA) for 2008 to a team based at Boston University Medical (BUMC) and Charles River Campuses and Boston Medical Center (BMC). These awards, together with 12 CTSAs awarded in 2007, and 12 awarded in 2006, form the core of an NIH effort to build a national consortium of select centers that will transform how clinical and translational research is conducted, ultimately enabling researchers to provide new and better treatments more efficiently and quickly to patients.

The Boston University Clinical and Translational Science (BU-BRIDGE) Institute will integrate, connect and expand research and programs across traditional academic departments and schools. The institute will be a bridge between disciplines to facilitate interactions by incorporating multiple key programs that support the university-wide commitment to a home for translational research.

The BU-BRIDGE Institute will build on a strong foundation of relationships and trust that presently exists. Moreover, we expect the Institute and its community engagement function to have a transformative effect on clinical and translational research at BUMC by infusing community-based needs and perspectives throughout the Institutes work, said David Center, MD, principal investigator for this project and associate provost for Translational Research, the Gordon and Ruth Snider Professor of Pulmonary Medicine at BUSM and Chief, Pulmonary, Allergy and Critical Care Medicine at BMC.

Importantly, the Institute will provide the administrative structure and process, as well as financial resources, to significantly extend and enhance our successful partnering with our community, Center added.

The CTSA will allow the Institute to build on existing strengths to create an environment linking faculty, trainees and university programs to speed the translation of innovations in medical science to improve maintenance of health and diagnosis and treatment of diseases and share these innovations with other University based Clinical and Translational Science Institute's. The BU-BRIDGE environment will also support the bi-directional development and translation of ideas that begin in the clinic to the BU scientific community and back to identify new ways to improve health and delivery of health care services. Moreover, the Institute will significantly enhance existing partnerships with Boston's community health centers, transforming the conduct of clinical and translational research by infusing it with community based perspectives and needs.

Our program is a confirmation of the close collaboration among the three Boston University Medical Campus schools, Boston Medical Center, the Boston HealthNet Health Centers and Boston Universitys Charles River Campus, said Karen Antman, MD, dean of Boston University School of Medicine and provost of Boston University Medical Campus.

With more than half of NIHs funding allocated for basic research, the CTSA consortium is perfectly poised to help move discoveries in the laboratory to improved patient care. The consortium serves as the bridge in this process that allows researchers to perfect and refine existing treatments through interdisciplinary teams that extend to the clinic and community, said NIH Director Elias A. Zerhouni, MD. Through the consortium, we are better able to leverage expertise and resources across the CTSA institutions, and ultimately maximize NIHs investment in basic research, which should remain a top priority.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8491
Boston University
Source:Eurekalert

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially ... their medication by matching users with high quality water pipes within an ideal price ... commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, who use ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
(Date:6/23/2016)... , ... June 23, 2016 , ... Representatives of CHA ... the newest member of their staff, Dr. Joshua J. Berger. As of May ... of the world-renowned facility. , Dr. Berger has received recognition for his research, his ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: